Kurt Graves - Pulmatrix Director
| PULM Stock | USD 2.02 0.00 0.00% |
Director
Mr. Kurt C. Graves is an Director of the Company. effective May 2010. Mr. Graves has served as executive chairman and chief executive officer of Intarcia Therapeutics a biotechnology company since September 2010 and was an independent consultant since October 2009. Prior to joining Intarcia Therapeutics Mr. Graves served as Executive Vice President Chief Commercial Officer and Head of Corporationrationrate and Strategic Development at Vertex Pharmaceuticals a pharmaceutical company from July 2007 to November 2009. From January 1999 to July 2007 Mr. Graves held various positions at Novartis International AG a pharmaceutical company most recently as Global Head of the General Medicines Business Unit and Chief Marketing Officer for the pharmaceuticals division. Prior to Novartis International AG Mr. Graves held commercial and general management positions of increasing responsibility at Merck Worldwide and Astra Merck Pharmaceuticals. Mr. Graves currently serves as chairman of the board of directors of Intarcia Therapeutics and a director of Achillion Pharamaceuticals Inc. and is also a director of several private biopharmaceutical companies. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended executive leadership programs at Harvard Wharton School of Management and University of Michigan since 2010.
| Age | 47 |
| Tenure | 14 years |
| Address | 99 Hayden Avenue, Lexington, MA, United States, 02421 |
| Phone | 781 357 2333 |
| Web | https://www.pulmatrix.com |
Pulmatrix Management Efficiency
The company has return on total asset (ROA) of (0.246) % which means that it has lost $0.246 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5752) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Pulmatrix's Total Current Assets are very stable compared to the past year. As of the 25th of April 2024, Net Tangible Assets is likely to grow to about 37.6 M, while Non Current Assets Total are likely to drop about 8.2 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Louis Manzo | Capricor Therapeutics | 76 | |
| Helen Kim | Assembly Biosciences | 54 | |
| Gaggar | Instil Bio | 85 | |
| Peter Feldschreiber | Akari Therapeutics PLC | N/A | |
| Birgitte Volck | Soleno Therapeutics | 55 | |
| Mason Freeman | Crinetics Pharmaceuticals | 66 | |
| James Meyers | CytomX Therapeutics | 54 | |
| Stephanie Okey | Crinetics Pharmaceuticals | 58 | |
| Robert Ward | Akari Therapeutics PLC | 60 | |
| Mahendra Shah | Soleno Therapeutics | 70 | |
| David Byrne | Akari Therapeutics PLC | N/A | |
| Douglas Morris | Bio Path Holdings | 68 | |
| Stuart Collinson | Soleno Therapeutics | 59 | |
| Clive Richardson | Akari Therapeutics PLC | N/A | |
| Wayne Kauth | Instil Bio | 79 | |
| Mark Cohen | Akari Therapeutics PLC | 46 | |
| Heath Cleaver | Bio Path Holdings | 42 | |
| Mark Auerbach | Assembly Biosciences | 78 | |
| Matthew Young | CytomX Therapeutics | 49 | |
| Amy Sing | Bio Path Holdings | 57 | |
| Marion McCourt | CytomX Therapeutics | 58 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.25 |
Pulmatrix Leadership Team
Elected by the shareholders, the Pulmatrix's board of directors comprises two types of representatives: Pulmatrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulmatrix. The board's role is to monitor Pulmatrix's management team and ensure that shareholders' interests are well served. Pulmatrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulmatrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, Interim Officer | ||
| Terrance McGuire, Director | ||
| Matthew Sherman, Director | ||
| David Hava, Chief Scientific Officer | ||
| Alexander Klibanov, Founder | ||
| Akihisa Akao, Director | ||
| James Roach, Chief Medical Officer | ||
| Michael Higgins, Director | ||
| Steven Gillis, Director | ||
| Jean Sung, Vice President - Pharmaceutical Development | ||
| William Duke, CFO, Principal Financial Officer & Principal Accounting Officer | ||
| Robert Clarke, CEO and President and Director | ||
| Scott Rocklage, Director | ||
| Kurt Graves, Director | ||
| Richard Conley, Independent Director | ||
| Mark Iwicki, Chairman of the Board | ||
| Amit Munshi, Director | ||
| Gregory French, Independent Director | ||
| Margaret MD, Chief Officer | ||
| Ted Raad, CEO, Director | ||
| David JD, Advisor | ||
| Aidan Curran, VP Affairs | ||
| Teofilo MBA, CEO President | ||
| Teofilo Raad, CEO, Director |
Pulmatrix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulmatrix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (1.93) % | ||||
| Operating Margin | (1.01) % | ||||
| Current Valuation | (3.04 M) | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Institutions | 8.59 % | ||||
| Number Of Shares Shorted | 2.66 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 0.44 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pulmatrix in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pulmatrix's short interest history, or implied volatility extrapolated from Pulmatrix options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pulmatrix using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Pulmatrix Stock analysis
When running Pulmatrix's price analysis, check to measure Pulmatrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmatrix is operating at the current time. Most of Pulmatrix's value examination focuses on studying past and present price action to predict the probability of Pulmatrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmatrix's price. Additionally, you may evaluate how the addition of Pulmatrix to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Pulmatrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.87) | Revenue Per Share 1.998 | Quarterly Revenue Growth 0.289 | Return On Assets (0.25) | Return On Equity (0.58) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.